Search

Corvus Pharmaceuticals Inc

Geschlossen

11.64 -1.27

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.59

Max

11.72

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+153.87% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-80M

1B

Vorheriger Eröffnungskurs

12.91

Vorheriger Schlusskurs

11.64

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Sept. 2026, 23:56 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

25. Sept. 2026, 23:55 UTC

AtriCure Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average despite retracing some initial gains.

25. Sept. 2026, 23:55 UTC

Wendy's Co saw modest gains during after-market hours on Friday, continuing its upward movement but remaining below its 20-day moving average.

25. Sept. 2026, 23:55 UTC

Lexicon Pharmaceuticals Inc is rising in after-market trading, gaining ground since Friday's close, marking a notable divergence from four consecutive sessions of losses.

25. Sept. 2026, 23:55 UTC

Cognizant Technology Solutions Corp is trading modestly higher in after-market hours, reaching a peak return since Friday's close, despite remaining below its 20-day moving average.

25. Sept. 2026, 23:51 UTC

Hamilton Beach Brands Holding Co has advanced in after-market trading, significantly above its 20-day moving average and near the upper end of its one-month range.

25. Sept. 2026, 23:51 UTC

Social Media

Darden Restaurants Inc reported a rise in sales to $3.2 billion, but net income fell, leading to a decline in stock price in after-market trading.

25. Sept. 2026, 23:51 UTC

News

CDW Corp completed its acquisition of Lovelytics, enhancing its Services and Solutions portfolio, as shares advanced in after-market trading.

25. Sept. 2026, 23:51 UTC

Krispy Kreme Inc is advancing in after-market trading, showing a notable increase since Friday's close, despite being below its 20-day moving average.

25. Sept. 2026, 23:51 UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, reflecting a notable decline since Friday's close and today's sharp loss.

25. Sept. 2026, 23:51 UTC

News

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

25. Sept. 2026, 23:51 UTC

Southern Co is trading slightly higher in after-market hours, though its price remains below the 20-day moving average after four consecutive lower closes.

25. Sept. 2026, 23:51 UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to reflect cautious market sentiment amid agricultural sector challenges and external economic pressures.

25. Sept. 2026, 23:51 UTC

S&P/Case-Shiller Index Forecasts 2.2% Year-over-Year Home Price Increase Amid Mixed Housing Sentiment and Rising Treasury Yields

25. Sept. 2026, 23:51 UTC

South Korea's S&P Global Manufacturing PMI set for October 1 release amid slowing growth and geopolitical tensions impacting market sentiment.

25. Sept. 2026, 23:50 UTC

Southern Missouri Bancorp Inc is trading modestly lower in after-market hours, positioned below its 20-day moving average and near the lower end of its one-month range.

25. Sept. 2026, 23:50 UTC

Upstart Holdings Inc is trading modestly higher in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

25. Sept. 2026, 23:50 UTC

ABM Industries Inc is down in after-market trading, moving from a slight dip to a more pronounced decline since Friday's close.

25. Sept. 2026, 23:50 UTC

Arcus Biosciences Inc is trading lower in after-hours, reaching its lowest point of the day and remaining well below its 20-day moving average.

25. Sept. 2026, 23:50 UTC

Ambarella Inc is rising in after-market trading, continuing its positive trend and remaining significantly above its 20-day moving average.

25. Sept. 2026, 23:50 UTC

Recursion Pharmaceuticals Inc has advanced in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month trading range.

25. Sept. 2026, 23:50 UTC

Etsy Inc. has advanced in after-market trading, despite a notable decline from its earlier high and positioning below its 20-day moving average.

25. Sept. 2026, 23:50 UTC

Baker Hughes Co is trading modestly higher in after-market hours, showing unusual upward movement despite remaining below its 20-day moving average.

25. Sept. 2026, 23:50 UTC

Altria Group Inc is experiencing a slight increase in after-market trading, advancing since Friday's close despite some unusual activity and price retracement.

25. Sept. 2026, 23:50 UTC

Medtronic PLC is down in after-market trading, continuing a seven-session trend of lower finishes and remaining significantly below its 20-day moving average.

25. Sept. 2026, 23:50 UTC

Tencent Music Entertainment Group declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above its 20-day moving average.

25. Sept. 2026, 23:46 UTC

Parker-Hannifin Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

25. Sept. 2026, 23:46 UTC

Northern Oil and Gas Inc is trading modestly higher in after-market hours, reaching a peak return since Friday's close, though still below its 20-day moving average.

25. Sept. 2026, 23:46 UTC

Modest increase in after-market trading, peak return near 0.9%.

25. Sept. 2026, 23:46 UTC

Correlated Moves

Alaska Air Group Inc's shares are trading roughly flat in after-market hours, reflecting routine activity amid slight gains in the Fidelity Enhanced Small Cap Core ETF.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

153.87% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD  153.87%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.